Abcuro Raises $66 Million to Fund Second Registrational Attempt in Inclusion-Body Myositis

Company: Abcuro · Event Type: Series D Financing · Product: Ulviprubart (ABC008) · Mechanism: Anti-KLRG1 Monoclonal Antibody · Indication: Inclusion-Body Myositis · Announcement Date: August 18, 2026 Summary Abcuro closed a $66 million Series D financing to fund a new, potentially registrational study of ulviprubart…